

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450

P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DA	ATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/511,661	10/18/2004		Conrad P. Dorn	21058YP	4903
210 MERCK AND	7590 CO INC	08/07/2007		EXAMINER	
P O BOX 2000				O SULLIVAN, PETER G	
RAHWAY, N	HWAY, NJ 07065-0907			ART UNIT	PAPER NUMBER
				1621	
				MAIL DATE	DELIVERY MODE
				08/07/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

· · · · · · · · · · · · · · · · · · ·	Application No.	Applicant(s)					
	10/511,661	DORN ET AL.					
Office Action Summary	Examiner	Art Unit					
	Peter G. O'Sullivan	1621					
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING D  - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period in Failure to reply within the set or extended period for reply will, by statute and the period of the period of the maximum statutory period in the period for reply will, by statute and the period of the period o	ATE OF THIS COMMUNICATION 136(a). In no event, however, may a reply be timwill apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONEI	I. ely filed the mailing date of this communication. O (35 U.S.C. § 133).					
Status	•						
1) Responsive to communication(s) filed on	Responsive to communication(s) filed on						
•	·						
closed in accordance with the practice under l	Ex parte Quayle, 1935 C.D. 11, 45	3 O.G. 213.					
Disposition of Claims	•	•					
4)  Claim(s) 1-11 is/are pending in the application 4a) Of the above claim(s) is/are withdra 5)  Claim(s) is/are allowed. 6)  Claim(s) is/are rejected. 7)  Claim(s) is/are objected to. 8)  Claim(s) 1-11 are subject to restriction and/or	wn from consideration.						
Application Papers							
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) accomposed and applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Example 11.	cepted or b) objected to by the E drawing(s) be held in abeyance. See tion is required if the drawing(s) is obj	e 37 CFR 1.85(a). ected to. See 37 CFR 1.121(d).					
Priority under 35 U.S.C. § 119							
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of:  1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority application from the International Burea * See the attached detailed Office action for a list	ts have been received. ts have been received in Application trity documents have been receive u (PCT Rule 17.2(a)).	on No d in this National Stage					
Attachment(s)  1) Notice of References Cited (PTO-892)	4) Interview Summary	(PTO-413)					
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	Paper No(s)/Mail Da 5) Notice of Informal Pa	te					

Application/Control Number: 10/511,661

Art Unit: 1621

Restriction to one of the following inventions is required under 35 U.S.C. 121:

Claims 1-8, drawn to aminoalkylphenols, classified in class 564, subclass
 355+.

II. Claims 9-11, drawn to methods of treating malaria with aminoalkylphenols or combinations with other anti-malarial agents, classified in class 514, subclass 311+.

The inventions are distinct, each from the other because of the following reasons:

Inventions I and II are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product. See MPEP § 806.05(h). In the instant case the instant compounds could be used as anti-oxidants. Additionally, the treatment of malaria with pharmaceutical combinations is outside of the scope of the compounds of claim 1.

Because these inventions are independent or distinct for the reasons given above and there would be a serious burden on the examiner if restriction is not required because the inventions have acquired a separate status in the art due to their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Applicants are further required to elect a single disclosed species, i.e. a single disclosed compound if group I is elected or a single disclosed compound or combination of compounds if group II is elected.

Application/Control Number: 10/511,661 Page 3

Art Unit: 1621

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

Any inquiry concerning this communication should be directed to Peter G. O'Sullivan at telephone number (571)272-0642.

PETER O'SCULIVAN PRIMARY EXAMINER GROUP 1200